Clinical Trial: A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naive Extensive-Stage Small Cell Lung Cancer

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07802821) titled 'A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naive Extensive-Stage Small Cell Lung Cancer' on Aug. 30.

Brief Summary: This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 in combination with QL2107 versus Tislelizumab plus platinum and etoposide as first-line treatment in participants with extensive-stage small cell lung cancer.

Study Start Date: Oct. 15

Study Type: INTERVENTIONAL

Condition: Extensive-stage Small Cell Lung Cancer

Intervention: DRUG: QLC5508

QLC5508 will be a...